Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$4.3B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's ongoing development efforts and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, its work is significant as it aims to improve treatment options for patients with various types of cancer, a major area of medical need.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of -$0.86, which was better than the expected -$1.07, showing a 19.63% surprise. The stock rose by 8.23% the following day, indicating positive market reaction despite the loss.

Management Promises & Guidance

Continue to advance clinical trials for its cancer therapies.
Focus on improving operational efficiencies.
Enhance communication with investors regarding future developments.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and ability to beat EPS estimates in previous quarters.

Bull Case

If Celcuity can demonstrate significant progress in its clinical trials and report a smaller-than-expected loss, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to show meaningful advancements or reports a larger loss than anticipated, it could result in a negative market response.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements have been made in clinical trials for the company's cancer therapies?

This information will be critical in assessing the company's growth potential and market position.

How does management plan to address operational efficiencies moving forward?

Investors will be looking for concrete plans to improve financial performance and reduce losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Celcuity's therapies to gain traction in the market, given their unique approach to cancer treatment.

Supporting Evidence

Celcuity has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages suggest, indicating heightened investor interest.

The company's recent advancements in clinical trials may not be fully reflected in current market expectations.

Key Risk

If clinical trial results show significant promise, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve its financial performance against ongoing development costs.

Bull Confirmed If

A reported EPS loss of less than $0.80 would confirm the bull case and suggest strong operational progress.

Bear Confirmed If

An EPS loss exceeding $1.00 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.4% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests a potential stock increase of around 3.4%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 2.4%, reflecting investor disappointment and concerns over the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for cancer therapies.
2Details on cost management strategies and operational efficiencies.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their therapies based on recent feedback.
5Management's outlook on future revenue streams and profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's ongoing development efforts and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

Management Promises & Guidance

Continue to advance clinical trials for its cancer therapies.
Focus on improving operational efficiencies.
Enhance communication with investors regarding future developments.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and ability to beat EPS estimates in previous quarters.

Bull Case

If Celcuity can demonstrate significant progress in its clinical trials and report a smaller-than-expected loss, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to show meaningful advancements or reports a larger loss than anticipated, it could result in a negative market response.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements have been made in clinical trials for the company's cancer therapies?

This information will be critical in assessing the company's growth potential and market position.

How does management plan to address operational efficiencies moving forward?

Investors will be looking for concrete plans to improve financial performance and reduce losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Celcuity's therapies to gain traction in the market, given their unique approach to cancer treatment.

Supporting Evidence

Celcuity has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages suggest, indicating heightened investor interest.

The company's recent advancements in clinical trials may not be fully reflected in current market expectations.

Key Risk

If clinical trial results show significant promise, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve its financial performance against ongoing development costs.

Bull Confirmed If

A reported EPS loss of less than $0.80 would confirm the bull case and suggest strong operational progress.

Bear Confirmed If

An EPS loss exceeding $1.00 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests a potential stock increase of around 3.4%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 2.4%, reflecting investor disappointment and concerns over the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for cancer therapies.
2Details on cost management strategies and operational efficiencies.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market demand for their therapies based on recent feedback.
5Management's outlook on future revenue streams and profitability.